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Abstract 
Background: The artemisinin anti-malarials are widely deployed as artemisinin-based combination therapy (ACT). 
However, they are not recommended for uncomplicated malaria during the first trimester because safety data from 
humans are scarce.
Methods: This was a prospective cohort study of women of child-bearing age carried out in 2011–2013, evaluating 
the relationship between inadvertent ACT exposure during first trimester and miscarriage. Community-based surveil-
lance was used to identify 1134 early pregnancies. Cox proportional hazard models with left truncation were used.
Results: The risk of miscarriage among pregnancies exposed to ACT (confirmed + unconfirmed) in the first trimester, 
or during the embryo-sensitive period (≥6 to <13 weeks gestation) was higher than among pregnancies unexposed 
to anti-malarials in the first trimester: hazard ratio (HR) = 1.70, 95 % CI (1.08–2.68) and HR = 1.61 (0.96–2.70). For 
confirmed ACT-exposures (primary analysis) the corresponding values were: HR = 1.24 (0.56–2.74) and HR = 0.73 
(0.19–2.82) relative to unexposed women, and HR = 0.99 (0.12–8.33) and HR = 0.32 (0.03–3.61) relative to quinine 
exposure, but the numbers of quinine exposures were very small.
Conclusion: ACT exposure in early pregnancy was more common than quinine exposure. Confirmed inadvertent 
artemisinin exposure during the potential embryo-sensitive period was not associated with increased risk of miscar-
riage. Confirmatory studies are needed to rule out a smaller than three-fold increase in risk.
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Background
Artemisinin-based combination therapy (ACT) anti-
malarials have been adopted as first‐line treatment for 
falciparum malaria in almost all endemic countries, 
providing life‐saving benefits to children, adults and 
pregnant women globally [1]. However, their safety is 
uncertain when used in early pregnancy. Ascertainment 
of risk from exposure to anti-malarials in the first trimes-
ter is difficult in resource-poor settings and data avail-
able for assessing risk are limited [2, 3]. Artemisinins 
are embryo-toxic in several animal species, including 
non-human primate models [4, 5]. Teratogenic effects 
observed in mice and rabbits included death of the foe-
tus, malformations of the heart, great vessels, and limb 
defects. Primate models exposed to prolonged courses 
of ACT had high rates of foetal loss [6]. Animal mod-
els suggested that artemisinin embryo-toxicity targets 
primitive erythroblasts, which are the primary form of 
red blood cells in circulation between weeks 4 and 10 
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post-conception in humans. Therefore the embryo-sen-
sitive period to artemisinin, if any, is thought to occur at 
6–12 (inclusive) weeks’ gestation from the first day of the 
last menstrual period (LMP) in humans [4, 5, 7, 8].
There are limited data available to assess whether ACT 
is embryo-toxic or teratogenic in humans; fewer than 
700 exposures in the first trimester have been well doc-
umented [9–15]. After reviewing all existing evidence in 
2003 and then in 2006, the World Health Organization 
(WHO) recommended that artemisinins could be used 
during the second or third trimesters of pregnancy and 
that, due to insufficient safety data, treatment in the first 
trimester was not recommended unless the life of the 
mother is at risk, or oral quinine is not available [5, 16]. 
The recommended treatment for first trimester malaria 
infections is seven days’ oral quinine alone or combined 
with clindamycin [17]. However, as women may not be 
aware of their pregnancy or do not declare an early preg-
nancy, and because clinic staff do not often assess for 
pregnancy in women of child-bearing age (WOCBA), the 
risk of exposure to drugs not recommended in pregnancy, 
including to potential teratogens, is possible during this 
period [18]. As ACT is increasingly available, a growing 
number of women will be inadvertently exposed to an 
artemisinin compound in early pregnancy, including dur-
ing the period when foetal organs and tissues are formed.
Malaria can have severe consequences to the health 
of the pregnant woman and her unborn baby including 
maternal anaemia, foetal loss, preterm birth, low birth 
weight and perinatal mortality, and in some cases mater-
nal death. The impact of malaria infection in early preg-
nancy has been identified as a major knowledge gap for 
estimating the burden of malaria in pregnancy. Recent 
studies have provided insight into the potential adverse 
consequences of malaria infections early in pregnancy, 
showing a major impact on birth weight and maternal 
anaemia [19, 20]. Findings from a retrospective analysis 
from 25  years of data from the Thai-Myanmar border, 
where artemisinin deployment has been necessary for 
many years because of multi-drug resistance, showed 
that malaria infection in the first trimester (both sympto-
matic and asymptomatic) was a significant risk factor for 
miscarriage. No association between first trimester arte-
misinin exposure and miscarriage was found. However 
more data from a wider range of malaria-endemic coun-
tries are required to provide an increased level of reas-
surance that first trimester artemisinin exposure does 
not significantly increase the risk of miscarriage or other 
adverse pregnancy outcomes. The findings from a pro-
spective cohort study of WOCBA designed to examine 
whether ACT exposure in the first trimester was associ-
ated with miscarriage are reported here.
Methods
Overview of study design
This was a prospective cohort study conducted among 
WOCBA (15–49  years of age) residing in a highly 
malarious area in western Kenya with a population 
under continuous health and demographic surveillance 
system (HDSS) monitoring as part of the collabora-
tion between the Kenya Medical Research Institute 
(KEMRI) and Centers for Disease Control and Pre-
vention (CDC) [21]. Participants received treatment 
through the usual channels, including health facilities 
and drug outlets.
Procedures
Recruitment of women of child‑bearing age 
and pregnancy detection
Between 15 February, 2011 and 15 February, 2013, 
6010 WOCBA participating in an ongoing population-
based, infectious disease, surveillance project (PBIDS) 
in rural Bondo District, western Kenya [22, 23] (Addi-
tional file 1) were invited to participate in the ‘Evalua-
tion of Medications used in Early Pregnancy’ (EMEP) 
prospective cohort study. EMEP staff visited all homes 
in the PBIDS and enrolled consenting WOCBA who 
met eligibility criteria for EMEP. WOCBA were eligi-
ble for EMEP if they were between 15 and 49 years of 
age and active participants of PBIDS. Exclusion cri-
teria included: inability to give informed consent or 
provide an accurate medical history. WOCBA who 
consented to participate were asked if they could be 
pregnant and offered a pregnancy test at the time of 
enrolment and again approximately every 3  months 
thereafter. Any participant with a detected pregnancy 
was referred to the antenatal clinic at Lwak Hospital 
where trained EMEP nurses confirmed the pregnancy 
(either by ultrasound if the women presented before 
24  weeks, or by palpation and by auscultation of the 
foetal heart later in pregnancy) and offered free ante-
natal care (ANC). Additionally, all pregnant patients 
presenting at the ANC clinic of Lwak Hospital were 
enrolled if all criteria were met. EMEP nurses were not 
involved in treatment of study participants.
Gestational age assessment
Gestational age was determined using the most accu-
rate measurement available for each participant in the 
following order: ultrasound scan taken before 24 weeks’ 
gestation performed by trained study nurses (Sonosite 
180 plus portable ultrasound system), Ballard estimates 
measured within 96  h of birth, LMP or reported gesta-
tion at time of pregnancy loss, and, lastly gestational age 
derived from fundal height assessment (Additional file 1).
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Pregnancy outcome
Pregnancy outcomes were assessed using a combina-
tion of health facility- and home-based follow-up vis-
its. The latter is particularly relevant for miscarriages, 
because the vast majority of these events occur in the 
community, not in health facilities. Village-based staff 
received monthly lists of participants with estimated 
delivery dates and after visiting the participants’ homes 
they informed study nurses of pregnancy outcomes. Fol-
low-ups by study staff were then arranged to administer 
structured questionnaires about the delivery, outcome, 
any illnesses and medication used during pregnancy. 
Pregnancy outcomes captured included: pregnancy loss 
(miscarriages, induced abortions and stillbirths), live 
births and major congenital malformations detectable 
at birth by surface examination. This analysis focuses on 
miscarriage defined as spontaneous pregnancy loss at or 
before 28 completed weeks’ gestation (2–28 weeks inclu-
sive), which is considered the gestational age of viability 
in resource-constrained settings.
Anti‑malarial drug exposure ascertainment
Drug exposure data were captured using three 
approaches (Table  1): (a) interviews with pregnant 
women visiting the antenatal clinic in Lwak Hospital and 
at the time of pregnancy outcome follow-up (henceforth 
referred to as EMEP data); (b) record linkage to data on 
drugs prescribed to WOCBA at the outpatient depart-
ment in Lwak Hospital (henceforth referred to as Lwak-
OPD data); and, (c) weekly to twice monthly home visits 
by fieldworkers as part of PBIDS.
Other covariates
Obstetric history and ANC laboratory information col-
lected routinely at antenatal booking (haemoglobin 
level, HIV and syphilis testing, and malaria microscopy) 
were extracted from the ANC records at Lwak hospital 
or antenatal cards by study nurses. Demographic char-
acteristics and medical history, including illnesses (e.g., 
malaria) and drugs used during the current pregnancy 
were collected at each EMEP study visit at ANC and dur-
ing pregnancy outcome follow-up visits. Household level 
wealth quintiles were obtained from the HDSS [24].
Data analysis
Exposure definition
A trend of increase in risk of miscarriage with ACT expo-
sure during this artemisinin-specific, embryo-sensitive 
period would corroborate the biological mechanism 
observed in animal models and suggest a causal associa-
tion with ACT exposures. The analysis focused on two 
exposure definitions: anti-malarial drug reported/pre-
scribed (1) ‘anytime’ in the first trimester, i.e., gestational 
week 2 and 0  days (day 14 since LMP) to week 13 and 
6  days (day 97 since LMP) post-LMP, and (2) between 
weeks 6  day 0 (day 42 since LMP) to week 12  day 6 
post-LMP (day 90 since LMP) (potential artemisinin 
embryo-sensitive period as suggested by animal repro-
toxicology [8]). Unexposed was defined as no evidence 
of anti-malarial or malaria exposure in any of the three 
data sources. Confirmed exposures were defined as expo-
sures identified by at least two of the three data sources. 
Confirmed  +  unconfirmed exposures were defined as 
Table 1 Description of drug information sources used to determine anti-malarial and malaria exposure status
ANC antenatal care, EMEP evaluation of medications used in early pregnancy study, Lwak OPD Lwak hospital out-patient department, PBIDS population-based 
infectious disease surveillance
Approach Format Drug information available
EMEP self-report Retrospective self-report of illness and medication used since 
the beginning of the pregnancy collected at every ANC visit 
and at pregnancy outcome follow-up visit. A general open 
question about any drug use as well as a directed question 
for specific anti-malarials were included as using medication/
indication-specific questions have been shown to improve 
accuracy. Photographs of all anti-malarial drugs found in the 
study area were used to facilitate recognition of drug names. A 
calendar marking public holidays and school closures was also 




Number of tablets per day
Indication and indication diagnosis
Drug source
Lwak-OPD records Prospective documentation by health facility clinic staff of 
diagnosis and treatment prescribed at outpatient department 
(OPD) whenever a PBIDS participant sought care at Lwak 




PBIDS weekly and twice-monthly 
home visits
Self-report of symptoms, health-seeking behaviour and medica-
tion. This information was collected continuously on a weekly 
(from 5 January, 2010 to 26 May, 2011) and then twice-
monthly basis (27 May, 2011 onwards). The same visual aids as 
described above were used for recall of drug intake
Date of visit
Symptoms in previous week/2 weeks
Treatment taken for the symptoms including 
drug name
If and where care was sought
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anti-malarial identified by at least one of the three data 
sources.
Cox regression model
Analyses were performed using Stata v12.1 (StataCorp 
LP, College Station, TX, USA). Cox proportional haz-
ard regression models with left truncation were fitted 
to estimate the effect on miscarriage of ACT exposure 
during the first trimester and during the artemisinin 
embryo-sensitive period. Exposure was treated as a time-
dependent variable (Additional file 1). Known risk fac-
tors for miscarriage were considered and to determine 
which variables remained in the final model, assessment 
of confounding was based on the impact a variable had 
on the hazard ratio, followed by the consideration of its 
precision. If the HR changed by ≥10 % the variable was 
retained in the model [25, 26].
The primary analysis compared the hazard of miscar-
riage among pregnancies with confirmed ACT expo-
sures, either anytime during the first trimester or six to 
12 weeks post-LMP, with the hazard among women not 
exposed to any anti-malarials anytime during the first tri-
mester or among women exposed to quinine anytime in 
the first trimester or 6–12 weeks post-LMP.
Secondary analyses consisted of similar models but 
using (a) less restrictive exposure definitions, including 
both confirmed and unconfirmed exposures, and, (b) 
more restrictive exposure definitions where only ACT 
exposures within estimated gestational age confidence 
margins were included (Additional file 2).
Ethical review and consent
The EMEP study was approved by the ethics commit-
tees and institutional review boards of CDC (No. 5889), 
KEMRI (No. 1752) and the Liverpool School of Tropi-
cal Medicine (No. 09.70). Written informed consent 
or assent was obtained from each participant includ-




Out of 5911 eligible WOCBA, 5536 (94  %) consented 
to participate and among them, 1453 pregnancies were 
detected, and 1134 (78 %) were included in the data anal-
ysis (Fig. 1). The mean and median gestational age at time 
of pregnancy detection was 13.3 (standard deviation 6.9) 
and 12.1 (range 0–27.9) weeks (Table 2). Overall, 62 % of 
deliveries took place at a health facility, and 25 % of the 
miscarriages. Overall, 67 % of pregnancy outcomes were 
captured within a week of the event; however, for miscar-
riages this was only 20 %. 
Prevalence of first trimester ACT and quinine exposure
Overall, 299 (26.4  %) of the 1134 pregnancies had evi-
dence of possible ACT exposure anytime in the first tri-
mester (confirmed  +  unconfirmed). For 77 (25.8  % of 
exposures and 6.8 % of all pregnancies) this could be con-
firmed by at least two of the three sources; 56 of these 
confirmed exposures (18.7, 5.3  % of pregnancies) were 
within the estimated gestational age confidence mar-
gins. For 212 out of 299 first trimester exposures (70.9 %, 
18.7  % of pregnancies), the exposure occurred between 
6 and 12  weeks’ gestation; 47 of them were confirmed 
exposures (Fig. 2). Only 13 pregnancies were exposed to 
quinine-alone anytime in the first trimester, and 11 dur-
ing the 6–12 weeks’ gestational period.
Association between first trimester ACT‑exposure 
and miscarriage
Confirmed exposure (primary analysis)
Compared to pregnancies without anti-malarial expo-
sure/malaria in the first trimester (793), the hazard 
for miscarriage was non-significantly higher among 
women with confirmed ACT exposures anytime in the 
first trimester (77) [hazard ratio (HR)  =  1.24, 95  % CI 
(0.56–2.73)], and this was HR = 1.72 (0.66–4.45) in mul-
tivariate analysis (Fig.  2). The corresponding values for 
ACT exposure during the embryo-sensitive period (47) 
were HR = 0.73 (0.19–2.82) and HR = 0.81 (0.21–3.03) 
(Fig. 2).
The values when compared against quinine (13) were: 
HR = 0.99 (0.12–8.33) and HR = 0. 32 (0.03–3.61) (crude 
analysis) for exposure anytime and six to 12 weeks post-
LMP (Fig. 2).
More restrictive definitions to define exposure within 
the redefined margins for gestational age resulted in simi-
lar or lower effect estimates, but numbers of exposures 
and events were limited (Additional file 2). The method 
used for missing value did not alter the conclusions 
(Additional file 3).
Confirmed + unconfirmed exposure (secondary analysis)
When using a less restrictive definition of exposure by 
including unconfirmed exposures as well, the risk of 
miscarriages was significantly higher among the ACT-
exposed pregnancies relative to unexposed pregnan-
cies: adjusted HR = 1.66 (1.04–2.67). This was HR = 1. 
61 (0.96–2.70) for the embryo-sensitive period. The HRs 
when compared to quinine were HR = 0.64 (0.08–4.91) 
and HR = 0.46 (0.05–4.44), respectively (Fig. 2).
Discussion
Pregnancies exposed to ACT in the first trimester were 
at increased risk of miscarriage compared to pregnancies 
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not exposed to anti-malarials in the same gestation 
period. This was only statistically significant at the 5  % 
level in the group with the less restrictive definition for 
exposure (confirmed and unconfirmed) which had higher 
number of events (29) and exposures (299) [adjusted 





♦ Not meeting inclusion criteria (n=99)
♦ Declined to participate (n=375)
Consented (n=5536)
Pregnancies (n=1453)
Number of pregnancies per participants:
♦ Single pregnancy (n=1266)
♦ Two pregnancies (n=92)
♦ Three pregnancies (n=1)
Follow-Up 
Enrolment
Loss to follow-up (n=85)
♦ Migrated (n=67)
♦ Withdrawal or refused follow-up (n=13)




Excluded from analysis (n=319)
♦Detected at outcome (n=33)
♦ Entered after 28 weeks (n=219)
♦No GA information (n=21)
♦Pregnancy end date error (n=5)
♦No follow-up (n=41)
Fig. 1 Study participant flow diagram from screening to inclusion in data analysis
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[HR = 1.72 95 % CI (0.66–4.45)] was obtained when the 
analysis was restricted to those exposures that could be 
confirmed by the OPD database or the ongoing house-
hold surveillance, which was the primary analysis. How-
ever the available exposures (77) and events (six) were 
reduced markedly with this more restrictive analysis and 
the difference was not statistically significant. When the 
analysis was further restricted to exposures in the poten-
tial embryo-sensitive period in humans for the arte-
misinins, the effect estimates were again similar [HR = 1. 
61 95  % CI (0.96, 2.70)] for confirmed  +  unconfirmed 
exposures, but much lower for confirmed exposures 
[HR  =  0.73 95  % CI (0.19, 2.82)]. However this latter 
analysis, which was also part of the primary analysis, 
included only two events and 47 pregnancies exposed to 
ACT. There was no evidence for an increase in the risk 
of miscarriage among women treated with ACT versus 
women treated with oral quinine, but again the number 
exposed to quinine alone was limited to 13 with only one 
miscarriage.
It was expected that the risk of miscarriage would 
be higher among women who received anti-malarials 
than among women without anti-malarial exposure 
early in pregnancy. This is related to the potential for 
Table 2 Characteristics of 1134 pregnancies by ACT exposure status [n (%) otherwise stated]
ACT artemisinin combination therapy, SD standard deviation
* P values refer to Pearson Chi square test for categorical variables and ANOVA test for continuous variables
a Gestational age lowest estimate include 0 which reflects inaccuracy in the gestational age measurements
b HIV status information was not available for 12 % (129) of pregnancies that did not attend antenatal care or have the antenatal card for review. HIV status 
information was complemented by HDSS and data which offered home-based HIV testing and counselling to PBIDS participants. Test results were linked to the 
study participants using unique ID and missing data were updated if the test was performed before the pregnancy detection for HIV positive test results and for HIV 
negative results if the test was performed maximum 3 months before or after pregnancy detection. An additional 30 HIV status were ascertained while 8 % (99) still 
had no HIV status data
Overall  
(N = 1134)
No ACT exposure  
in the first trimester 
(N = 835)
Unconfirmed ACT  
exposure in the first 
trimester (N = 222)
Confirmed ACT  
exposure in the first 
trimester (N = 77)
P values*
Age in years [mean (SD; 
range)]
26.1 (6.8; 15–47) 26.1 (6.7; 15–45) 26.7 (7.2; 15–47) 25.2 (6.5; 16–41) 0.225
Gravidity Missing n = 16 Missing n = 14 Missing n = 1 Missing n = 1 0.065
Primigravidae 219 (19.6) 151 (18.4) 47 (21.3) 21 (27.6)
1–3 pregnancies 525 (47.0) 405 (49.3) 90 (40.7) 30 (39.5)
4+ pregnancies 374 (33.5) 265 (32.3) 84 (38.0) 25 (32.9)
Previous pregnancy loss 160 (14.3), Missing n = 17 118 (14.4), Missing n = 15 30 (13.6), Missing n = 1 12 (15.8), Missing n = 1 0.888
Gestational age at detec-
tion in weeks [mean (SD; 
range)]a
13.3 (6.9; 0–27.9) 13.3 (7.0; 0–27.9) 13.0 (6.7; 0.3–27) 13.6 (7.1; 2.4–27.4) 0.770
Occupation Missing n = 31 Missing n = 28 Missing n = 1 Missing n = 2 0.191
Not working 379 (34.4) 281 (34.8) 68 (30.8) 30 (40.0)
Farming 369 (33.5) 268 (33.2) 80 (36.2) 21 (28.0)
Small business/Skilled 
Labour
335 (30.4) 246 (30.5) 65 (29.4) 24 (32.0)
Other 20 (1.8) 12 (1.5) 8 (3.6) 0
Antenatal care summary
 Number of ANC visit Missing n = 39 Missing n = 31 Missing n = 5 Missing n = 3 0.125
 None 89 (8.1) 64 (8.0) 21 (9.7) 4 (5.4)
 1 90 (8.2) 61 (7.6) 24 (11.1) 5 (6.8)
 2 155 (14.2) 121 (15.1) 25 (11.5) 9 (12.2)
 3 244 (22.3) 193 (24.0) 38 (17.5) 13 (17.6)
 4+ 517 (47.2) 365 (45.4) 109 (50.2) 43 (58.1)
Gestational age at first 
ANC visit in weeks 
[mean (SD)]*
20.8 (7.8) range: 1.7–41.0 21.24 (7.8) range: 2.7–41.0 19.7 (7.6) range: 1.7–41.0 19.4 (7.7) range: 3.4-37.0 0.020
HIV positiveb Missing n = 101 Missing n = 79 Missing n = 18 Missing n = 4 0.354
Negative 771 (74.4) 562 (74.3) 149 (73.0) 60 (82.2)
Positive 262 (25.4) 194 (25.7) 55 (27.0) 13 (17.8)
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confounding by indication, i.e., women treated with ACT 
or quinine sought treatment because of their malaria 
or other febrile illness, whereas women who did not 
require anti-malarials did not. The comparison with 
untreated women is therefore difficult to interpret as it 
does not allow for the differentiation between the effects 
of malaria and the drug treating it. Malaria itself, even 
if it remains asymptomatic, is a known cause of miscar-
riage. A recent meta-analysis of five trials with malaria 
chemoprophylaxis or intermittent preventive therapy in 
2876 paucigravidae in sub-Saharan Africa showed that 
women in the control arms were at a 1.54 95 % CI (0.98–
2.44) higher risk of miscarrying than women protected 
by chemoprevention [27]. Prospective studies in low 
malaria-transmission areas in Thailand also found that 
asymptomatic malaria in the first trimester increased the 
odds of miscarriage nearly three-fold and symptomatic 
infections four-fold [13]. The 1.4- to 1.7-fold increased 
risk for miscarriage among women exposed to ACT or 
quinine relative to pregnancies not requiring treatment 
observed in this study is thus within the expected range 
of malaria-associated risk of miscarriage.
This study is underpowered to confidently detect or 
exclude effects smaller than a three-fold increased risk of 
miscarriage associated with ACT. Nevertheless no indi-
cation for such a potential association was found. First, 
there was no indication that the effect size associated 
with ACT exposure relative to unexposed women was 
greater among women treated during the embryo-sensi-
tive period than at anytime during the first trimester. If 
ACT was causing miscarriage through this mechanism, 
the effect size would be expected to be highest for expo-
sures restricted to that embryo-sensitive period. No such 
trend was observed. Secondly, the rates of miscarriage 
in the quinine-only and ACT-exposed pregnancies were 
similar. Although the comparison with quinine needs to 
be interpreted with caution due to the small numbers of 
quinine-only exposed women, these results are consist-
ent with observations from the Thai-Burmese border by 
McGready et al. They also found no difference in the pro-
portions of pregnancies ending in miscarriages between 
women treated with chloroquine (26 %), quinine (27 %) 
or artesunate (31  %) [13]. A recent prospective study 
from Tanzania reported higher risk of pregnancy loss 
(miscarriage and stillbirth combined) in women exposed 
to quinine compared to those exposed to ACT [14]. A 
prospective study in Zambia found higher occurrence of 
miscarriage in first trimester ACT-exposed pregnancies 
(5  %) compared to none in those exposed to sulfadox-
ine-pyrimethamine or quinine but the number exposed 
to quinine (six) were too small to allow for a meaningful 
comparison [12].
The small number of quinine exposures in the first 
trimester in this study was surprising as this is the 
Fig. 2 Miscarriage rate, unadjusted and adjusted hazard rates for the association between different anti-malarial exposure categories and miscar-
riage
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recommended first-line malaria treatment in the first tri-
mester. However these observations are consistent with 
a recent study on malaria in pregnancy-prescribing prac-
tice carried out in the same area of western Kenya (Riley 
et al., unpublished) and a study from Uganda [28]. These 
studies draw attention to the need to assess reasons for 
poor adherence to quinine and malaria treatment guide-
lines. Poor tolerability and poor compliance to its seven-
day regimen is a known problem for treatment of malaria 
with oral quinine [29, 30].
This study had several limitations that should be con-
sidered. First, the small number of quinine exposures 
limited the ability to compare ACT-exposed pregnancies 
to the purported ‘control’ drug (as quinine is not known 
to cause miscarriages) [3]. Second, it was not possible to 
control for confounding by indication (i.e., the disease 
itself ) because laboratory confirmation of malaria was 
not available for most women. Controlling for malaria 
and its severity is important, as malaria itself has been 
suggested to reduce the potential risk of embryo-tox-
icity from artemisinin as was found in rat models [31]. 
Third, since induced abortions are illegal in Kenya, this 
could have resulted in induced abortions being reported 
as miscarriages. However since neither ACT nor qui-
nine exposures are perceived as indications for induced 
abortion in this population, it is thus unlikely that such 
misclassification would differ according to exposure sta-
tus. Fourth, it was not possible to account for exposure 
misclassification due to lack of adherence to prescribed 
medication (drug intake was not observed) or from coun-
terfeit anti-malarials [32], which could bias the estimate 
towards the null. Fifth, the ability to confirm exposure 
was limited because there was limited overlap in the 
exposures ascertained in the three data sources. The 
group at highest risk for bias are the unconfirmed expo-
sure cases as 32 first-trimester, ACT-exposures were only 
reported after pregnancy outcome. Recall bias following 
adverse pregnancy outcome has been well documented, 
hence the focus in this study was to confirm ACT expo-
sures using prospective drug ascertainment approaches 
through record linkage to minimize such bias [33–35]. 
Another potential source of exposure misclassification is 
gestational age measurement errors. The study could not 
assess any dose–response effect of exposure.
Conclusion
The results presented here are consistent with two pre-
vious observational studies showing an increased risk of 
miscarriage among women treated for malaria with ACT 
in the first trimester versus unexposed women, and a 
similar [13] or lower risk compared to oral quinine [14]. 
These results also suggest that ACT use in the first tri-
mester is much more common than quinine. The risk 
associated with malaria in early pregnancy, the compara-
ble observed risk between ACT and quinine exposures, 
and the limited compliance to treatment with quinine 
suggests a trial comparing ACT versus quinine for the 
treatment of uncomplicated malaria in the first trimes-
ter may be merited. Before such a trial is considered, 
further safety data on the association between ACT and 
congenital malformations, that is forthcoming from stud-
ies conducted by the Malaria in Pregnancy Consortium 
and WHO, should be reviewed and all available evidence 
pooled to evaluate the evidence of the risk and benefits of 
artemisinin use in early pregnancy.
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